The high prevalence of SWI/SNF mutations in various human malignancies, the occurrence of SMARCA4 as the driver mutation in SCCOHT and the potential therapeutic strategy of EZH2 inhibitors led us to explore the role of SMARCA4 and EZH2 in epithelial ovarian cancers. Here, SMARCA4 is linked to ovarian carcinoma.